Clinical Trials Logo

Brain Diseases clinical trials

View clinical trials related to Brain Diseases.

Filter by:

NCT ID: NCT05033327 Completed - Cirrhosis, Liver Clinical Trials

Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis

Start date: April 20, 2021
Phase: N/A
Study type: Interventional

The personalized nutrition and exercise app was designed for use by individuals living with chronic conditions. The pilot study examines the acceptance and use of the online, interactive program to support self-management in cirrhosis.

NCT ID: NCT05007353 Recruiting - Alzheimer Disease Clinical Trials

The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) Study

SINGER
Start date: August 23, 2021
Phase: N/A
Study type: Interventional

A study in Finland found that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. A 6-month pilot study was initiated in Singapore, which demonstrated the cultural feasibility and practicality of the FINGER interventions and a set of locally adapted interventions in an Asian population. The SINGER study is a 2-year randomized controlled trial that aims to test the efficacy and safety of these lifestyle changes, including diet and cardiovascular risk factor management, cognitive and physical exercises, in delaying cognitive decline in older adults at risk of dementia.

NCT ID: NCT04992195 Recruiting - Stroke Clinical Trials

Impact of COVID-19 Vaccines on Cerebrovascular Health

Start date: July 5, 2021
Phase:
Study type: Observational

Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future. On the other hand, vaccination hesitancy has emerged as a major hindrance on the global vaccination campaigns in certain areas due to safety concerns, social factors, and public health policies. For instance, a recent survey conducted in Hong Kong showed a low vaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination events relayed by the social media maybe reasons for vaccination hesitancy. Among which, cerebrovascular accidents (CVA) after vaccination were one of the most frequently reported post-vaccination events. These reports ranged from ischemic strokes in elderly patients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise "young-and-fit" adults. While many of these events were investigated by the COVID-19 immunization expert committee, an important premise to address the apprehension of CVA after vaccination is the provision of evidence-based information of the impact of COVID-19 vaccines on brain health. In this prospective, longitudinal, observational study, we aim to elucidate the relationship between COVID-19 vaccines and cerebrovascular health in healthy citizens in a population-based cohort.

NCT ID: NCT04985539 Recruiting - Parkinson Disease Clinical Trials

The Personalized Parkinson Project de Novo Cohort

PPP-novo
Start date: August 29, 2020
Phase:
Study type: Observational

Currently, the Movement Disorders Society (MDS)-UPDRS scale remains the gold standard to document the outcomes in clinical trials for Parkinson's disease (PD). The MDS-UPDRS is far from infallible, as it is based on subjective scoring (using a rather crude ordinal score), while execution of the tests depends on clinical experience. Not surprisingly, the scale is subject to both significant intra- and inter-rater variability that are sufficiently large to mask an underlying true difference between an effective intervention and placebo. Digital biomarkers may be able to overcome the limitations of the MDS-UPDRS, as they continuously collects real-time data, during the patient's day to day activities. In this study the investigators are interested in developing algorithms to track progression of bradykinesia, gait impairment, postural sway, tremor, physical activity, sleep quality, and autonomic dysfunction (the latter being derived from e.g. skin conductance and changes in heart rate variability).

NCT ID: NCT04973332 Completed - Clinical trials for Cerebrovascular Disorders

Safety and Efficacy of SINOMED SR for Endovascular Treatment of Acute Ischemic Stroke

Start date: August 8, 2021
Phase: N/A
Study type: Interventional

A prospective, multicenter, randomized controlled, non-inferiority study to investigate the effectiveness and safety of SINOMED SR for endovascular treatment of acute ischemic stroke

NCT ID: NCT04970355 Completed - Cluster Headache Clinical Trials

Efficacy of Erenumab in Chronic Cluster Headache

CHERUB01
Start date: December 2, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of erenumab in participants with chronic cluster headache.

NCT ID: NCT04954248 Recruiting - Covid19 Clinical Trials

Pilot Study for PET/MR Imaging of Covid-19

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The primary goal of this project is to study the feasibility of a prototype brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of metabolism and perfusion in Covid-19 negative and positive/once positive subjects. This study serves as a pilot study for establishing an imaging protocol for combined PET and MR derived functional information as well as MRI acquired anatomical information.

NCT ID: NCT04950270 Recruiting - Clinical trials for Posterior Reversible Encephalopathy Syndrome

Copeptin Kinetics in Critically Ill Patients With Posterior Reversible Encephalopathy Syndrome

XPRESSE
Start date: June 18, 2022
Phase:
Study type: Observational

XPRESSE is a multicenter observational prospective biomarker study in which critically ill patients with MRI-based PRES diagnosis will have copeptin kinetics from a daily blood sample for 6 days and a 3-month follow-up. This study aims to investigate the relationship between copeptin and PRES in order to establish the optimal therapeutic time window for vaptan treatment against PRES. Data collection using an electronic case report form will include demographic data, medical history and data related to PRES: onset modalities and date of symptoms control, radiological features of PRES, biological investigations, results of etiological investigations and therapeutic management (e.g., anticonvulsants, antihypertensive drugs, supportive treatments). Outcomes will include modified Rankin scale score and Glasgow Outcome Scale score at ICU discharge, 3-month modified Rankin Scale score and 3-month mortality.

NCT ID: NCT04948138 Completed - MELAS Syndrome Clinical Trials

Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome

Start date: June 28, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assesses the efficacy of oral supplementation with glutamine over three months on several amino acids and lactate concentration measured in cerebrospinal fluid and cerebral lactate measured by magnetic resonance spectroscopy.

NCT ID: NCT04940416 Terminated - Cirrhosis Clinical Trials

Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease

Start date: August 31, 2017
Phase:
Study type: Observational

This study involves utilizing a noninvasive computer application (Neurofit) that performs oculometric assessment of dynamic visual processing in patients with liver cirrhosis to see if the presence of advance liver disease influences eye movement metrics.